Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

Satsuma Pharmaceuticals, a US-based migraine treatment developer backed by spinout-focused investment firm Osage University Partners, has filed to raise up to $86.3m in an initial public offering. Founded in 2016, Satsuma is developing an acute migraine treatment, STS101, that will administer a dry-powder formulation of a chemical compound known as dihydroergotamine mesylate through a nasal…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.